Assessment of New Protected Mechanism of Liraglutide on CKD Progression

Abstract

Podocyte injury represents the main reason for proteinuria and renal disease in diabetic and non-diabetic patients. Recently Liraglutide as a GLP-1 analog is hypothesized to play a vital role in preventing kidney damage by antiinflammatory and anti-apoptotic effect mechanisms. This study was established to evaluate the effect of Liraglutide on deterioration that happens with time in chronic kidney disease. 36 male Wister rats with a weight of 250-300 g were used in this study. All selected animals were examined and determined to be normal on general examination. Rats were divided into three groups (12rats/group): control group: negative control group injected normal saline I.P, induction group: single I.P dose (7.5 mg/kg) of doxorubicin for 14 days then administered 0.5ml/kg normal saline intraperitoneal for 28 days, and treatment group: single I.P dose (7.5 mg/kg) of doxorubicin for 14 days then administered I.P Liraglutide 200μg/kg/day freshly dissolve in 0.5ml /kg normal saline 28 days. The treatment group appeared significantly decreased (P< 0.05) in the pro-inflammatory expression of TNF-α as compared with the induction group, while the treatment group revealed a significant increased (P< 0.05) in the expression of anti-apoptotic BCL-2 in the proximal tubule of the kidney. Besides the effect of Liraglutide on renal deterioration by lowering blood glucose, the main causes of oxidative stress, Liraglutide as GLP-1 analog can reduce the consequence of proteinuria in the cases of glomerulosclerosis and tubulointerstitial damage by decreased pro-inflammatory TNF-α expression and increase expression of BCL-2 in that cell.